MedImmune Announces Research Collaboration with UC SanFrancisco - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

MedImmune Announces Research Collaboration with UC SanFrancisco

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 3
MedImmune, the biologics research and development arm of AstraZeneca, has entered into a three-year collaboration with the Clinical and Translational Science Institute (CTSI) at the University of California, SanFrancisco (UCSF). The collaboration will focus on CTSI’s Catalyst Awards program, which solicits applications from University scientists who wish to move their translational research into product development.

This marks the first industrial partnership for CTSI’s Catalyst Awards program’s therapeutic track, which focuses specifically on discovery and development of patient treatment options. The collaboration will benefit both MedImmune’s biologics and AstraZeneca’s small molecule portfolios and will call for proposals in therapeutic areas of interest to MedImmune and AstraZeneca, including cardiovascular and metabolic disease, oncology, respiratory, inflammation and autoimmunity, neuroscience and infectious disease.

Financial terms around the collaboration were not disclosed.

Source: MedImmune

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here